Synthesis, characterization and antitumor activity of a poly-4-Vinyl pyridine-co-cannabidiol polymer
Metadatos
Mostrar el registro completo del ítemAutor
Fuentes-Ríos, David; Moya-Utrera, Federico; Moreno, Javier; Mesas Hernández, Cristina; Doña Flores, Manuel; Sarabia, Francisco; López-Romero, J. Manuel; Melguizo Alonso, Consolación; Prados Salazar, José CarlosEditorial
Elsevier
Materia
CBD co-polymer CBD solubility Lung cancer
Fecha
2024-08-06Referencia bibliográfica
Fuentes Ríos, D. et. al. 219 (2024) 113328. [https://doi.org/10.1016/j.eurpolymj.2024.113328]
Patrocinador
Andalusian Government: FQM397 and UMA20 FEDERJA84 Projects.Resumen
Due to its natural origin and numerous beneficial properties, cannabidiol (CBD), one of the major phytocannabinoids
of the Cannabis sativa L., has attracted the attention of many research groups in recent years. In this
work, we prepared 4-vinylpyridine (4VP) and CBD co-polymeric nanoparticles (solid@poly-4VP-co-CBD) using
N,N’-methylenbisacrylamide (BIS) as cross-linker, and in which CBD is covalently incorporated into the polymeric
structure. We evaluated particle morphology by Transmission Electron Microscopy (TEM), while
compositional analyses were carried out by Nuclear Magnetic Resonance (NMR) spectroscopy, MALDI mass
spectrometry, and Raman and Energy Dispersive X-Ray (EDX) spectroscopies. Moreover, the antitumor effect was
analyzed in A549 human lung cell lines, using cell cycle analysis and antiproliferative assays. Interestingly, the
polymeric drug retained the cytotoxic and antiproliferative effects of CBD. This fact shows that the solid@poly-
4VP-co-CBD system can be considered as a new polymeric drug (PD) and may have an enormous potential since
it can make up for the shortcomings of the use of free drugs such as low stability or bioavailability.





